Latest & greatest articles for amiodarone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on amiodarone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on amiodarone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for amiodarone

1. Meta-Analysis Comparing the Relative Risk of Adverse Events for Amiodarone Versus Placebo

Meta-Analysis Comparing the Relative Risk of Adverse Events for Amiodarone Versus Placebo Amiodarone has been associated with adverse events that may restrict its use. We performed a meta-analysis of placebo-controlled trials to assess the relative risk of adverse events of amiodarone compared with placebo. In total, 43 randomized trials were included. A total of 11,395 patients were included (5,792 patients randomized to amiodarone and 5,603 patients randomized to placebo). The incident rate (...) of adverse events per 10,000 person-years was higher in the amiodarone group compared with placebo for pulmonary (129 vs 74; relative risk (RR) 1.77, p = 0.002), thyroid (201 vs 42; RR 4.44, p <0.001), hepatic (54 vs 25; RR 2.27, p = 0.01), cardiac (771 vs 450; RR 1.94, p <0.001), neurological (140 vs 76; RR 1.93, p <0.001), and skin (81 vs 23; RR 1.99, p = 0.04) adverse events. Low-dose amiodarone was not associated with statistically significant increase in pulmonary adverse events but was still

2019 EvidenceUpdates

2. Amiodarone and acupuncture (AA) for cardiac arrhythmia (CA): study protocol for a systematic review

Amiodarone and acupuncture (AA) for cardiac arrhythmia (CA): study protocol for a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web

2019 PROSPERO

3. Thyroidectomy for Amiodarone-Induced Thyrotoxicosis: Mayo Clinic Experience (PubMed)

Thyroidectomy for Amiodarone-Induced Thyrotoxicosis: Mayo Clinic Experience Amiodarone-induced thyrotoxicosis (AIT) is a difficult diagnostic and management challenge, especially during severe thyrotoxicosis accompanied by cardiovascular compromise.To evaluate thyroidectomy for the management of AIT.Retrospective cohort study of adults with noncongenital heart disease with AIT after >3 months of amiodarone who underwent thyroidectomy from 1 November 2002 to 31 December 2016.Referral center.The

Full Text available with Trip Pro

2018 Journal of the Endocrine Society

4. Amiodarone

Amiodarone Top results for amiodarone - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for amiodarone The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you

2018 Trip Latest and Greatest

5. Amiodarone: Wonder Drug or Wonder Why?

Amiodarone: Wonder Drug or Wonder Why? Emergency Medicine > Journal Club > Archive > January 2018 Toggle navigation January 2018 Amiodarone: Wonder Drug or Wonder Why? Vignette Working in TCC can be draining, and on one particularly busy afternoon, you begin to suspect your own sanity. After back-to-back cardiac arrest patients, you wonder if perhaps you should have done something less stressful with your life, like maybe become a lobster boat captain or an ice road trucker. Your first code (...) is a middle-aged female who suffered cardiac arrest while watching Alabama beat Clemson during the Sugar Bowl (yeah...that's right!!!). She was initially noted to be in ventricular fibrillation (VF), and remained so after three rounds of defibrillation. As she arrives in the trauma room, you immediately continue CPR and set up to shock her again. Your attending orders amiodarone, and even though you remember hearing that this may not be very effective, you realize it's not the time to argue. The patient

2018 Washington University Emergency Medicine Journal Club

6. The influence of concomitant amiodarone on the effects of novel oral anticoagulants in patients with atrial fibrillation: a meta-analysis

The influence of concomitant amiodarone on the effects of novel oral anticoagulants in patients with atrial fibrillation: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2018 PROSPERO

7. Lower dose amiodarone are safe for current practice

Lower dose amiodarone are safe for current practice Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures Timing and effect

2018 PROSPERO

8. Efficacy and safety outcomes of non-vitamin k antagonist oral anticoagulants in patients with atrial fibrillation on amiodarone or polypharmacy: systematic review and meta-analysis

Efficacy and safety outcomes of non-vitamin k antagonist oral anticoagulants in patients with atrial fibrillation on amiodarone or polypharmacy: systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2018 PROSPERO

9. Amiodarone, lidocaine, magnesium or placebo in shock refractory ventricular arrhythmia: A Bayesian network meta-analysis. (PubMed)

Amiodarone, lidocaine, magnesium or placebo in shock refractory ventricular arrhythmia: A Bayesian network meta-analysis. Recent evidence challenges, the superiority of amiodarone, compared to other anti-arrhythmic medications, as the agent of choice in pulseless ventricular tachycardia (VT) or ventricular fibrillation (VF). We conducted Bayesian network and traditional meta-analyses to investigate the relative efficacies of amiodarone, lidocaine, magnesium (MgSO4) and placebo as treatments (...) ranking curve (SUCRA). Bayesian analysis demonstrated that lidocaine had superior effects on survival to hospital discharge, compared to amiodarone (OR, 2.18, 95% Cr.I 1.26-3.13), MgSO4 (OR, 2.03, 95% Cr.I 0.74-4.82) and placebo (OR, 2.42, 95% Cr.I 1.39-3.54). There were no statistical differences among treatment groups regarding survival to hospital admission/24 h (hrs) and return of spontaneous circulation (ROSC). Probability analysis revealed that lidocaine was the most effective therapy

2017 Heart & lung : the journal of critical care

10. In Patients With Cardiac Arrest, Does Amiodarone or Lidocaine Increase Meaningful Survival?

In Patients With Cardiac Arrest, Does Amiodarone or Lidocaine Increase Meaningful Survival? TAKE-HOME MESSAGE Among out-of-hospital cardiac arrest patients with shock-refractory ventricular tachycardia or ventricular ?brillation, neither amiodarone nor lidocaine increases survival to hospital discharge or good neurologic outcome. In Patients With Cardiac Arrest, Does Amiodarone or Lidocaine Increase Meaningful Survival? EBEM Commentators Benton R. Hunter, MD Paul I. Musey, MD Department (...) of Emergency Medicine Indiana University School of Medicine Indianapolis, IN Results Threerandomizedcontrolledtrials (n¼3,677) and 4 observational studies (n¼704) were included for meta-analysis out of 528 articles identi?edontheinitialsearch.The results were driven by a single large (n¼3,026) randomized controlled trial at low risk of bias. The 2 smaller randomized con- trolled trials had moderate risk of bias, and the observational studies were generally at low risk of bias. Both lidocaine and amiodarone

2017 Annals of Emergency Medicine Systematic Review Snapshots

11. Amiodarone for arrhythmia in patients with cardiac form of Chagas disease: a systematic review

Amiodarone for arrhythmia in patients with cardiac form of Chagas disease: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address

2017 PROSPERO

12. Amiodarone: A potential risk factor for retinal phototoxicity (PubMed)

Amiodarone: A potential risk factor for retinal phototoxicity To report the only known case, to our knowledge, of amiodarone induced retinal phototoxicity following vitrectomy surgery.A 66-year-old male presented with visual acuity of 20/150 OS secondary to an epiretinal membrane (ERM). Patient was on oral amiodarone for atrial fibrillation. Baseline spectral domain optical coherence tomography (SD-OCT) revealed an ERM with retinal thickening and schisis. The patient underwent an uncomplicated (...) showed resolution of macular edema, retinal pigment epithelium hyperplasia and an indistinct ellipsoid layer. Fluorescein angiography did not show any neovascularization. At three month follow-up, patient's vision, exam and OCT findings remained unchanged.Many pharmacologic agents have the ability to alter a patient's sensitivity to solar or artificial radiation. Drugs act as photosensitizers that lead to photochemical damage. Amiodarone has been reported to have such photosensitizing properties

Full Text available with Trip Pro

2016 American journal of ophthalmology case reports

13. Randomized comparison of intravenous procainamide vs. intravenous amiodarone for the acute treatment of tolerated wide QRS tachycardia: the PROCAMIO study (PubMed)

Randomized comparison of intravenous procainamide vs. intravenous amiodarone for the acute treatment of tolerated wide QRS tachycardia: the PROCAMIO study Intravenous procainamide and amiodarone are drugs of choice for well-tolerated ventricular tachycardia. However, the choice between them, even according to Guidelines, is unclear. We performed a multicentre randomized open-labelled study to determine the safety and efficacy of intravenous procainamide and amiodarone for the acute treatment (...) of tolerated wide QRS complex (probably ventricular) tachycardia.Patients were randomly assigned to receive intravenous procainamide (10 mg/kg/20 min) or amiodarone (5 mg/kg/20 min). The primary endpoint was the incidence of major predefined cardiac adverse events within 40 min after infusion initiation. Of 74 patients included, 62 could be analysed. The primary endpoint occurred in 3 of 33 (9%) procainamide and 12 of 29 (41%) amiodarone patients (odd ratio, OR = 0.1; 95% confidence interval, CI 0.03-0.6

Full Text available with Trip Pro

2016 EvidenceUpdates Controlled trial quality: predicted high

14. EMA recommends avoidance of certain hepatitis C medicines and amiodarone together

EMA recommends avoidance of certain hepatitis C medicines and amiodarone together EMA recommends avoidance of certain hepatitis C medicines and amiodarone together | European Medicines Agency Search Search Menu EMA recommends avoidance of certain hepatitis C medicines and amiodarone together Press release 24/04/2015 Concomitant use may increase risk of slow heart rate and related problems The European Medicines Agency (EMA) has confirmed a risk of severe bradycardia (slow heart rate) or heart (...) block (problems with conduction of electrical signals in the heart) when the hepatitis C medicines Harvoni (sofosbuvir with ledipasvir) or a combination of Sovaldi (sofosbuvir) and Daklinza (daclatasvir) are used in patients who are also taking the medicine amiodarone, which is an antiarrhythmic (a medicine used to treat irregular heartbeat). To manage this risk the Agency recommends that amiodarone should only be used in patients taking these hepatitis C medicines if other antiarrhythmics cannot

2016 European Medicines Agency - EPARs

15. Amiodarone versus Lidocaine for Arrhythmias: Comparative Clinical Effectiveness

Amiodarone versus Lidocaine for Arrhythmias: Comparative Clinical Effectiveness Amiodarone versus Lidocaine for Arrhythmias: Comparative Clinical Effectiveness | CADTH.ca Find the information you need Amiodarone versus Lidocaine for Arrhythmias: Comparative Clinical Effectiveness Amiodarone versus Lidocaine for Arrhythmias: Comparative Clinical Effectiveness Published on: January 8, 2016 Project Number: RB0949-000 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type (...) : Report Question What is the comparative clinical effectiveness of intravenous amiodarone versus intravenous lidocaine for patients in cardiac arrest or with life-threatening arrhythmias? Key Message One systematic review, two randomized controlled trials, and one non-randomized study were identified regarding intravenous amiodarone versus intravenous lidocaine for arrhythmias. Tags amiodarone, death, heart arrest, lidocaine, heart attack, Arrhythmias, Cardiac, Cardiac, Sudden Files Rapid Response

2016 Canadian Agency for Drugs and Technologies in Health - Rapid Review

16. Amiodarone method of administration for treatment of post-operative atrial fibrillation

Amiodarone method of administration for treatment of post-operative atrial fibrillation Amiodarone method of administration for treatment of post-operative atrial fibrillation Amiodarone method of administration for treatment of post-operative atrial fibrillation Mitchell MD, Strauss R, Mull N. Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation Mitchell MD, Strauss R, Mull N.. Amiodarone method of administration for treatment of post-operative atrial fibrillation. Philadelphia: Center for Evidence-based Practice (CEP). 2016 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Postoperative Period Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence

2016 Health Technology Assessment (HTA) Database.

17. Amiodarone for prevention of atrial fibrillation in cardiac surgery patients

Amiodarone for prevention of atrial fibrillation in cardiac surgery patients Amiodarone for prevention of atrial fibrillation in cardiac surgery patients Amiodarone for prevention of atrial fibrillation in cardiac surgery patients Mitchell MD, Reynolds CR, Mull N Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Mitchell MD, Reynolds CR (...) , Mull N. Amiodarone for prevention of atrial fibrillation in cardiac surgery patients. Philadelphia: Center for Evidence-based Practice (CEP). 2016 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Amiodarone; Atrial Fibrillation; Cardiac Surgical Procedures; Humans Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence Center for Evidence-based Practice, University

2016 Health Technology Assessment (HTA) Database.

18. The effect of prophylactic use of amiodarone on the incidence of atrial fibrillation in post-op CABG patients

The effect of prophylactic use of amiodarone on the incidence of atrial fibrillation in post-op CABG patients Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation

2016 PROSPERO

19. Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death. (PubMed)

Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death. Sudden cardiac death (SCD) is one of the main causes of cardiac death. There are two main strategies to prevent it: managing cardiovascular risk factors and reducing the risk of ventricular arrhythmias. Implantable cardiac defibrillators (ICDs) constitute the standard therapy for both primary and secondary prevention; however, they are not widely available in settings with limited resources (...) . The antiarrhythmic amiodarone has been proposed as an alternative to ICD.To evaluate the effectiveness of amiodarone for primary or secondary prevention in SCD compared with placebo or no intervention or any other antiarrhythmic drugs in participants at high risk (primary prevention) or who have recovered from a cardiac arrest or a syncope due to Ventricular Tachycardia/Ventricular Fibrillation, or VT/VF (secondary prevention).We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE

2015 Cochrane

20. Simeprevir with sofosbuvir: risk of severe bradycardia and heart block when taken with amiodarone

Simeprevir with sofosbuvir: risk of severe bradycardia and heart block when taken with amiodarone Simeprevir with sofosbuvir: risk of severe bradycardia and heart block when taken with amiodarone - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Simeprevir with sofosbuvir: risk of severe bradycardia and heart block when taken with amiodarone Avoid concomitant use of amiodarone with simeprevir (Olysio▼) and sofosbuvir (Sovaldi▼) combination therapy, unless other antiarrhythmics (...) cannot be given. Published 19 August 2015 From: Therapeutic area: , When treating patients with both heart rhythm disorders and hepatitis C: closely monitor patients taking amiodarone if they start taking the combination simeprevir and sofosbuvir; sofosbuvir and daclatasvir; and the fixed-dose combination of sofosbuvir and ledipasvir (particularly during the first weeks of treatment) only start amiodarone in patients taking any of these antiviral combinations when other antiarrhythmics

2015 MHRA Drug Safety Update